BIOLOGIC, DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Renflexis is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderately to severely active rheumatoid arthritis. Renflexis is indicated for use in combination with methotrexate. Renflexis is also referred to by its drug name, infliximab-abda.
Renflexis is a biosimilar of Remicade. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.
Renflexis is considered a biologic disease-modifying antirheumatic drug (DMARD). It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Renflexis is believed to work by attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. Renflexis binds to TNF-α and prevents it from signaling the immune system to attack the connective tissues.
How do I take it?
Renflexis is administered as an intravenous infusion every eight weeks after initial loading doses.
Renflexis is available in vial form.
The FDA-approved label for Renflexis lists common side effects including respiratory tract infections, infusion-related reactions, headache, and abdominal pain.
Rare but serious side effects listed for Renflexis can include severe infections, low blood cell counts, increased risk for lymphoma and other cancers, liver damage leading to liver failure, lupus-like syndrome, hepatitis B virus reactivation, heart failure, severe allergic reactions, and nerve conditions such as multiple sclerosis.
For more details about this treatment, visit:
Renflexis — Organon
Renflexis — Drugs.com